Merck Gardasil Sales Climb In Third Quarter; HPV Vaccine Generates $70 Mil.
Executive Summary
Merck's human papilloma virus vaccine Gardasil generated $70 mil. in sales during its first full quarter on the market, the company reported
You may also be interested in...
Therapeutic Biologics Approvals Up In 2006, Overall BLA Approvals Steady
Overall 2006 biological license application approvals held steady from 2005 at 10 approvals, but the year saw a significant increase in approvals of therapeutic biologics
Therapeutic Biologics Approvals Up In 2006, Overall BLA Approvals Steady
Overall 2006 biological license application approvals held steady from 2005 at 10 approvals, but the year saw a significant increase in approvals of therapeutic biologics
Gardasil Reimbursement Issues To Be Resolved In Early 2007, Merck Says
Merck expects reimbursement issues for its human papillomavirus vaccine Gardasil to be resolved by early 2007, Merck Vaccines President Margaret McGlynn said Dec. 12